Crescent Biopharma, Inc. (FRA:C68)
Germany · Delayed Price · Currency is EUR | Market Cap | 490.00M +128.6% |
| Revenue (ttm) | 10.40M |
| Net Income | -144.53M |
| EPS | -5.38 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 75 |
| Open | 11.00 |
| Previous Close | 11.00 |
| Day's Range | 11.00 - 11.00 |
| 52-Week Range | 6.70 - 22.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 6, 2026 |
About Crescent Biopharma
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is head... [Read more]
News
Crescent Biopharma completes dose escalation in ASCEND trial of CR-001
Crescent Biopharma (CBIO) announced clinical pipeline momentum, including enrolling patients in cohorts combining CR-001, a PD-1 x VEGF bispecific antibody, plus standard of care chemotherapy regimens...
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001
More than 125 patients dosed in ASCEND across the United States, Europe and South Korea; dose escalation complete On track to report initial monotherapy data from ASCEND in Q1 2027, including antitumo...
Crescent Biopharma Announces Grants of Inducement Awards
WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next ...
Crescent Biopharma upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright upgraded Crescent Biopharma (CBIO) to Buy from Neutral with a $36 price target The shares offer an attractive risk/reward ahead of Crescent’s catalysts in 2027, the analyst tells…
Crescent Biopharma announces FDA clearance of CR-002 IND application
Crescent Biopharma (CBIO) announced that the FDA has cleared its investigational new drug, or IND, application for CR-002, a topoisomerase inhibitor antibody drug-conjugate targeting programmed cell d...
Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
Phase 1/2 APOLLO global clinical trial to evaluate CR-002 in multiple solid tumor types, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), on track to ini...
Crescent Biopharma Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company is advancing a robust oncology pipeline with a PD-1/VEGF bispecific and ADCs, supported by a global partnership and efficient clinical trial design. Major data readouts are expected in 2027, with strong financial resources and a focus on rapid progression to phase III studies.
Crescent Biopharma Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Three oncology assets are advancing in the clinic, with global trials designed for rapid phase III starts and major data readouts expected in 2027. Strategic partnerships and innovative trial designs position the portfolio for broad combination therapy opportunities.
Crescent Biopharma to Present at September Investor Conferences
WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next...
Crescent Biopharma reports Q2 EPS (74c), consensus (64c)
“We have continued to demonstrate exceptional execution and are on track for multiple key clinical data readouts across our portfolio in 2027. The positive momentum in our ASCEND trial of…
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients CR-00...
Crescent Biopharma Earnings release: Q2 2026
Crescent Biopharma released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Crescent Biopharma Quarterly report: Q2 2026
Crescent Biopharma has published its Q2 2026 quarterly earnings report on July 30, 2026.
Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
WALTHAM, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next ...
Crescent Biopharma 8.095M share Spot Secondary priced at $14.50
Jefferies, TD Cowen, Guggenheim and Cantor Fitzgerald acted as joint book running managers for the offering.
Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
WALTHAM, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next ...
Crescent Biopharma files ordinary shares offering, no amount given
Jefferies, TD Cowen, Guggenheim, and Cantor are acting as joint book-running managers. LifeSci Capital is acting as a book-running manager.
Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
WALTHAM, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next ...
Crescent Biopharma Registration statement: Registration filing
Crescent Biopharma filed a registration statement on July 1, 2026, providing details about a securities offering with the SEC.
Crescent Biopharma Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The session highlighted a robust oncology pipeline with CR-001 as a potential next-generation backbone therapy, supported by innovative ADC combinations and a strong partnership with Kelun-Biotech. Key data readouts are expected in 2027, with a financial runway into 2028 and a focus on rapid, data-driven expansion across major cancer indications.
Crescent Biopharma Transcript: Jefferies Global Healthcare Conference 2026
HARMONi-6 and related data validate PD-1/VEGF bispecifics as a new backbone in immuno-oncology, showing strong efficacy and safety across tumor types. Strategic trial design, global considerations, and robust partnerships, especially with Kelun-Biotech, are driving pipeline expansion and positioning for leadership in the field.
Crescent Biopharma to Present at June Investor Conferences
WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next ...
Crescent Biopharma Transcript: AGM 2026
The meeting confirmed the election of two directors, ratified the auditor, and approved executive compensation and annual advisory votes on compensation. No shareholder questions were raised, and final vote results will be published in the minutes and Form 8-K.
Crescent Biopharma downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Crescent Biopharma (CBIO) to Neutral from Buy without a price target saying the ivonescimab copycat thesis is less compelling after Merck and Kelun’s sacituzumab tirumotecan...
Crescent Biopharma Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
The summit highlighted a robust oncology pipeline with four clinical studies launching this year, focusing on next-gen IO bispecifics and ADCs. Key data readouts are expected in 2027, leveraging strategic partnerships and a matrix portfolio approach to target multiple solid tumors and drive future development.